

In the claims

1-18. (Cancelled).

19. (Withdrawn) A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. (Withdrawn) A method for identifying a binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

21-23. (Cancelled).

24. (Withdrawn) A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11.

25. (Previously presented) An isolated protein comprising amino acid residues 1 to 627 of SEQ ID NO: 125.

26. (Previously presented) The isolated protein of claim 25 which comprises amino acid residues 2 to 627 of SEQ ID NO: 125.

27. (Previously presented) The isolated protein of claim 25 which comprises amino acid residues 27 to 627 of SEQ ID NO: 125.

28. (Previously presented) The protein of claim 25 which further comprises a polypeptide sequence heterologous to SEQ ID NO: 125.

29. (Previously presented) A composition comprising the protein of claim 25 and an acceptable carrier.
30. (Previously presented) An isolated protein produced by the method comprising:
 - (a) expressing the protein of claim 25 by a cell; and
 - (b) recovering said protein.
31. (Previously presented) An isolated protein comprising the amino acid sequence of the complete polypeptide encoded by the HOFND85 cDNA contained in ATCC Deposit No. PTA-1544.
32. (Previously presented) The isolated protein of claim 31 which comprises the amino acid sequence of the complete polypeptide encoded by the HOFND85 cDNA contained in ATCC Deposit No. PTA-1544, excepting the N-terminal methionine.
33. (Previously presented) The isolated protein of claim 31 which comprises the amino acid sequence of the secreted portion of the polypeptide encoded by the HOFND85 cDNA contained in ATCC Deposit No. PTA-1544.
34. (Previously presented) The protein of claim 31 which further comprises a polypeptide sequence heterologous to the HOFND85 cDNA contained in ATCC Deposit No. PTA-1544.
35. (Previously presented) A composition comprising the protein of claim 31 and an acceptable carrier.
36. (Previously presented) An isolated protein produced by the method comprising:
 - (a) expressing the protein of claim 31 by a cell; and
 - (b) recovering said protein.
37. (Previously presented) An isolated first polypeptide at least 90% identical to a second polypeptide consisting of amino acid residues 1 to 627 of SEQ ID NO: 125.

38. (Previously presented) The isolated polypeptide of claim 37, wherein said first polypeptide is at least 95% identical to said second polypeptide.
39. (Previously presented) The protein of claim 37 which further comprises a polypeptide sequence heterologous to SEQ ID NO: 125.
40. (Previously presented) A composition comprising the protein of claim 37 and an acceptable carrier.
41. (Previously presented) An isolated protein produced by the method comprising:
 - (a) expressing the protein of claim 37 by a cell; and
 - (b) recovering said protein.
42. (Previously presented) An isolated first polypeptide at least 90% identical to a second polypeptide consisting of the complete polypeptide encoded by the HOFND85 cDNA contained in ATCC Deposit No. PTA-1544.
43. (Previously presented) The isolated polypeptide of claim 42, wherein said first polypeptide is at least 95% identical to said second polypeptide.
44. (Previously presented) The protein of claim 42 which further comprises a polypeptide sequence heterologous to the HOFND85 cDNA contained in ATCC Deposit No. PTA-1544.
45. (Previously presented) A composition comprising the protein of claim 42 and an acceptable carrier.
46. (Previously presented) An isolated protein produced by the method comprising:
 - (a) expressing the protein of claim 42 by a cell; and
 - (b) recovering said protein.

47. (Currently amended) An isolated protein consisting of at least ~~[[30]]~~ 50 contiguous amino acid residues of amino acid residues 1 to 627 of SEQ ID NO: 125.
48. (Cancelled).
49. (Previously presented) The protein of claim 47 which further comprises a polypeptide sequence heterologous to SEQ ID NO: 125.
50. (Previously presented) A composition comprising the protein of claim 47 and an acceptable carrier.
51. (Previously presented) An isolated protein produced by the method comprising:
 (a) expressing the protein of claim 47 by a cell; and
 (b) recovering said protein.
52. (Currently amended) An isolated protein consisting of at least ~~[[30]]~~ 50 contiguous amino acid residues of the complete polypeptide encoded by the HOFND85 cDNA contained in ATCC Deposit No. PTA-1544.
53. (Cancelled).
54. (Previously presented) The protein of claim 52 which further comprises a polypeptide sequence heterologous to the HOFND85 cDNA contained in ATCC Deposit No. PTA-1544.
55. (Previously presented) A composition comprising the protein of claim 52 and an acceptable carrier.
56. (Previously presented) An isolated protein produced by the method comprising:
 (a) expressing the protein of claim 52 by a cell; and
 (b) recovering said protein.